

FORM 2B

LISTING SUMMARY

Issuer Name: Gemina Laboratories Ltd.		Listing Statement Date: August 5, 2021		
Descriptions of securities to be listed: Common Shares				
Address: 3800 Westbrook Mall, Suite 142, Vancouver, BC		Brief Description of the Issuer's Business: The Issuer is a biotechnology company that currently operates in the <i>In Vitro</i> Diagnostics market under the name "Gemina Labs." The Issuer's core competency lies in the development of novel surface functionalization chemistries for the detection of pathogens and biomarkers, the near-term application of which is in human health.		
Company Contact: John Davies		Description of securities outstanding		
Phone: 604 760-1997		Symbol GLAB	Type Common Shares	Number 50,237,959
		CUSIP 368650107		
Fax: N/A		If the Listing Statement was required to be filed because an event giving rise to material information has occurred that makes the previous Statement inaccurate or misleading, briefly describe the event: N/A		
E-mail: john.davies@psico.ca		Dates of Press Release and Any Public Filings Concerning the Event: N/A		
Jurisdiction of Incorporation: British Columbia		Date of Last Shareholders' Meeting and Date of Next Shareholders' Meeting (if scheduled): <ul style="list-style-type: none"> • N/A • Unknown at this time 		
Website: N/A				
Fiscal Year End: January 31				
Financial Information as at:		Board of Directors:		
	<u>January 31, 2021</u>	<u>April 30, 2021</u>	Name	Position
Current Assets	\$2,446,234	\$2,252,238	John Davies	CEO and Director
Working Capital	\$116,695	\$(505,102)	Robert Crandall Greene	CTO and Director
Total assets	\$2,527,100	\$2,238,326	David Rokoss	Director
Long-term liabilities	\$2,367,139	\$2,779,039	James Tansey	Director
Shareholders' equity	\$159,961	\$(450,713)	Martin Cronin	Director